Biopharmaceutical company ThromboGenics announced it intended to change its name to Oxurion NV to better reflect its activities and ambition to deliver eye disorder therapies.
Patrik De Haes, CEO, said "The new name, Oxurion, is designed to better reflect our ambition to deliver best in class therapies for back of the eye disorders. The renaming comes at a moment when we have reached important clinical milestones and are accelerating the execution of our unique pipeline of disease modifying compounds for diabetic eye disease. Moreover, we are also looking at expanding our drug development efforts into additional and new areas of back of the eye disease."
An extraordinary shareholder meeting on 27 July 2018 will vote on the name change and if approved will become effective in the week commencing 10 September 2018. The name change will also result in the company's stock ticker symbol changing from THR to OXUR.